Bioretec Ltd. has appointed Frank Sarcone as vice president of Sales for the United States and welcomed him to the firm’s management team. He reports to CEO Alan Donze. 
 
Sarcone has more than a quarter century of experience in the medical device sector, most of it with Cromwell, Conn.-based Integrated Medical Solutions, where he was CEO and founder for more than 17 years. Sarcone also served as chief executive at Promotus LLC and IMS Consulting LLC, where he drove significant revenue growth and spearheaded major sales initiatives. In addition, he was executive vice president of U.S. Sales at Elyptol, and regional sales manager for Stryker Endoscopy. In the latter position, Sarcone managed large teams and helped drive substantial increases in regional market share and revenue.  

Sarcone is recognized for his leadership, strategic acumen, ability to build and mentor high-performing teams, establishing long-lasting partnerships, and developing extensive networks within the medical device industry.
 
“Frank’s expertise and leadership style make him an invaluable addition to our team,” Donze said. “His ability to drive strategic initiatives and his deep understanding of the medical device market will be pivotal as we continue to expand our footprint and enhance our product offerings.”
 
Bioretec is a globally operating Finnish medical device company that develops biodegradable orthopedic implants. The company has built competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec is developing the new RemeOs product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their value-based healthcare targets while focusing on value for patients through efficient healthcare. The U.S. Food and Drug Administration approved the RemeOs trauma screw in March 2023.